© Reuters. FILE PHOTO: A sign stands outside a Abbvie facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo
(Reuters) – AbbVie Inc (NYSE:) said on Wednesday the U.S. Food and Drug Administration had declined to approve its Parkinson’s disease therapy for adults and had requested for more information on the device used to administer the treatment.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased